[CrossRef] [PubMed] [Google Scholar] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
The letter said some claims were false or misleading. This is important for patients reading marketing headlines
If you use or reference these findings, please include a link back to Levity with proper attribution
Protection of retinal pigment epithelium from oxidative injury by glutathione and precursors
Engineering quaternized chitosan in the 3D bacterial cellulose structure for antibacterial wound dressings
Hardan AY et al., A randomized controlled pilot trial of oral Nacetylcysteine in children with autism, 2012